Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Etanercept may not help some with suspected nonradiographic axial spondyloarthritis

Key clinical point: Patients with suspected nonradiographic axial spondyloarthritis but without positive MRI signs of sacroiliitis and/or elevated C-reactive protein levels show no response to etanercept.

Major finding: Researchers observed similar clinical improvements at 16 weeks in the etanercept and placebo arms of the study.

Study details: A randomized, double-blind, placebo-controlled trial in 80 patients with suspected nonradiographic axial spondyloarthritis.

Disclosures: The study was supported by an unrestricted financial grant from Pfizer and ReumaNederland. No conflicts of interest were declared.


Rusman T et al. Arthritis Rheumatol. 2020 Dec 5. doi: 10.1002/art.41607.